| HOME >> BIOLOGY >> TECHNOLOGY |
SANTA MONICA, Calif., March 19 /PRNewswire/ -- Kalologie Skincare today announced that Niv Edward Caviar, Executive Vice President of La Jolla Pharmaceutical Company, was elected to Kalologie Skincare's board of directors. Mr. Caviar previously served as Vice President of Allergan Inc.
"Niv is a strong marketer with solid operational skills," said William Brennan, Kalologie's CEO. "We look forward to benefiting from Niv's unique insight in the growing aesthetic skin care industry."
"Over the past five years, Kalologie has positioned itself to become a leading provider of aesthetic skin care products and services," said Niv Edward Caviar. "I look forward to working with the Company to help facilitate future growth, especially through the company's physician-only franchise program."
At Allergan, Mr. Caviar was Vice-President of Business Development and then Vice-President and Head of Marketing for Medical Dermatology. In his latter role, Mr. Caviar led all operational and strategic marketing activities for Allergan's U.S medical dermatology franchise. Brands under his responsibility included Tazorac(R), Avage(R), and Botox(R) for Medical Dermatology uses. Mr. Caviar is presently Executive Vice-President and Chief Business and Financial Officer of La Jolla Pharmaceutical Co., a San Diego-based biotech company focused on developing innovative pharmaceutical products. La Jolla Pharmaceutical's leading product in development is Riquent(R) (abetimus sodium), which is currently being studied to help treat and maintain remission in patients with lupus renal disease.
Mr. Caviar received an M.B.A. from Harvard University and a B.S. in
Mechanical Engineering from the U.S. Air Force Academy. Prior to his work
at Allergan, Mr. Caviar served as a captain in the U.S. Air Force where he
worked as a Solid Rocket Motor Engineer and was a Project Manager for the
U.S. Space Command on both the Titan IV Rocket and the Space Shuttle Solid
Rocket Motor Pr
'/>"/>
| SOURCE Kalologie Franchising, LLC Copyright©2008 PR Newswire. All rights reserved |